The ubiquitin/proteasome-dependent proteolytic pathway is an attractive target for therapeutics because of its critical involvement in cell cycle progression and antigen presentation. However ...

We believe that the ubiquitin/proteasome pathway is involved in so many cellular processes that it could not be properly described by a single model substrate and that the minimal requirement ...

BERLIN--(BUSINESS WIRE)--Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator ... proteins with the marker protein ubiquitin, leading to their degradation ...